FDA Authorizes Bivalent COVID-19 Boosters
FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.
FDA amended the emergency use authorizations of the Moderna and Pfizer-BioNTech COVID-19 vaccines on Aug. 31, 2022 to authorize bivalent formulations of the vaccines for use as a single booster dose two months after a primary or booster vaccination. The updated boosters contain both the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant. The Moderna vaccine is authorized for individuals aged 18 and older; the Pfizer-BioNTech vaccine for individuals aged 12 and older.
“The COVID-19 vaccines, including boosters, continue to save countless lives and prevent the most serious outcomes (hospitalization and death) of COVID-19,” said Robert M. Califf, Commissioner, FDA, in an agency press release. “As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose with a bivalent COVID-19 vaccine to provide better protection against currently circulating variants.”
According to the press release, these approvals were based on positive findings from separate clinical trials. Both trials found the immune response against BA.1 was stronger among participants who received the bivalent vaccine than those who had received the monovalent vaccine.
“The FDA has extensive experience with strain changes for annual influenza vaccines. We are confident in the evidence supporting these authorizations,” said Peter Marks, director of the Center for Biologics Evaluation and Research, FDA, in the press release. “The public can be assured that a great deal of care has been taken by the FDA to ensure that these bivalent COVID-19 vaccines meet our rigorous safety, effectiveness and manufacturing quality standards for emergency use authorization.”
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
